J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration
Executive Summary
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
You may also be interested in...
Janssen’s Newly Approved Ponvory Joins Crowded MS Space
Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.
Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
J&J Looks To Expand Spravato Label To Suicidal Ideation
The big pharma will seek the new indication later this year based on Phase III data showing a rapid decrease in depression symptoms, but without a significant improvement over placebo in suicidality.